Wegovy vs. Zepbound

Are Wegovy and Zepbound the same drug?

No — they are two different molecules from two different manufacturers. Wegovy is semaglutide, a single-hormone GLP-1 receptor agonist made by Novo Nordisk; Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist made by Eli Lilly [1], [2].

Both are once-weekly injections approved specifically for chronic weight management — but Zepbound acts on two gut-hormone receptors while Wegovy acts on one, which is the main reason their results differ when tested head-to-head [3].

The bigger picture: Wegovy, Zepbound, Ozempic, Mounjaro

Each molecule has a weight-loss brand and a diabetes brand, which is the source of most confusion:

• Semaglutide → Wegovy (weight management) and Ozempic (type 2 diabetes); also Rybelsus (oral diabetes tablet) [1].
• Tirzepatide → Zepbound (weight management + sleep apnea) and Mounjaro (type 2 diabetes) [2].

So Wegovy vs. Zepbound is the weight-loss matchup of the same two molecules behind Ozempic vs. Mounjaro — but here, both drugs are dosed and FDA-approved specifically for weight management.

What is Wegovy?

Wegovy (semaglutide) is a once-weekly injection FDA-approved for chronic weight management in adults and adolescents (12+) with obesity, or overweight plus a weight-related condition. In 2024 it also gained approval to reduce cardiovascular risk in adults with established heart disease and obesity or overweight, based on the SELECT trial [1], [6].

It titrates from 0.25 mg up to a maintenance dose of 2.4 mg once weekly. In its pivotal trial, STEP 1, Wegovy produced a mean −14.9% of body weight at 68 weeks, versus −2.4% on placebo [5].

What is Zepbound?

Zepbound (tirzepatide) is a once-weekly injection FDA-approved for chronic weight management — and, since 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity, the first drug approved for that condition [2].

It is a dual agonist (a "twincretin") that activates both the GIP and GLP-1 receptors, titrating from 2.5 mg up to 15 mg once weekly. In its pivotal obesity trial, SURMOUNT-1, Zepbound produced up to −20.9% of body weight at the 15 mg dose over 72 weeks [4].

How they work: one hormone vs. two

Both drugs mimic GLP-1, a gut hormone released after eating that curbs appetite, slows stomach emptying, and quiets "food noise" [1], [2]. Zepbound adds a second action on the GIP receptor, another incretin hormone involved in how the body handles food and energy.

This dual mechanism is the leading explanation for why tirzepatide tends to produce greater weight loss than a GLP-1-only drug such as semaglutide, though exactly how GIP adds benefit is still being studied [3].

Effectiveness: which works better for weight loss?

Zepbound produced more weight loss than Wegovy in the only trial that tested them head-to-head. In SURMOUNT-5, 751 adults with obesity but without diabetes were randomized to the highest tolerated dose of each drug.

At 72 weeks, the Zepbound group lost a mean −20.2% of body weight versus −13.7% on Wegovy, and Zepbound users were more likely to reach every milestone — at least 10%, 15%, 20%, and 25% of body weight [3].

For perspective, in a person starting at about 250 lb, −20.2% is roughly 50 lb versus about 34 lb at −13.7% — a difference of around 16 lb on average. Both are far beyond older weight-loss drugs, but Zepbound's dual-agonist edge is real and consistent. That said, individual response varies, and many people reach their goals on Wegovy [3], [5].

What to expect: timeline

Neither drug works overnight. Both start at a low dose and step up about every 4 weeks, so appetite eases within the first weeks while most of the weight comes off over the following months. In the trials, average weight loss was still building at 68–72 weeks — about 16–17 months — which is when the headline figures were measured [3], [4], [5].

Loss then tends to slow and plateau. Both are long-term treatments: when people stop, appetite returns and much of the lost weight typically comes back, which is why obesity is managed as a chronic condition over years [1], [2].

Beyond weight: heart health and sleep apnea

This is where the two drugs differentiate. Wegovy is FDA-approved to reduce the risk of major cardiovascular events in adults with obesity and established heart disease — in the SELECT trial it cut those events by about 20% versus placebo [1], [6].

Zepbound, meanwhile, is the first medication FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity [2]. So beyond the weight numbers, Wegovy carries the proven heart benefit, while Zepbound adds a sleep-apnea indication — a real consideration if you have either condition.

Dosing & administration

Both are once-weekly subcutaneous injections in prefilled pens, started low and titrated up about every 4 weeks to limit nausea [1], [2].

Wegovy dosing

0.25 → 0.5 → 1 → 1.7 → 2.4 mg maintenance, once weekly [1].

Zepbound dosing

2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg maximum, once weekly [2].

Side effects & safety

Side-effect profiles are very similar because both act on the same GLP-1 pathway — predominantly gastrointestinal, usually mild-to-moderate, and worst in the weeks after starting or moving up a dose. In the SURMOUNT-5 head-to-head, gastrointestinal events were the most common in both groups and most were mild to moderate [1], [2], [3].

Serious risks & boxed warning

Both carry a boxed warning for thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 [1], [2].

Less common but serious risks for both include pancreatitis, gallbladder disease, acute kidney injury (often from dehydration), and — for both — gallstones tied to rapid weight loss [1], [2].

Who should not take these (and key cautions)

Avoid either drug with a personal or family history of MTC or MEN 2, or a prior serious reaction to it [1], [2]. Use caution with a history of pancreatitis or gallbladder disease.

Because semaglutide clears slowly, Wegovy should be stopped at least 2 months before a planned pregnancy [1], and tirzepatide can make oral birth control less effective — switch to a non-oral method or add a barrier for 4 weeks after starting Zepbound and after each dose increase [2]. Share your full history with your clinician first.

Cost & insurance coverage

At list price, both run roughly $1,000–$1,350 per month before insurance [1], [2]. Coverage for weight-loss medication is inconsistent and varies widely by plan and employer — a major practical factor, since neither is reliably covered for obesity alone.

Manufacturer savings programs and lower-cost self-pay vial options can reduce the real cost, and a supervised medical weight-loss program like JumpstartMD's can change what you actually pay.

A note on compounded versions: compounded GLP-1 medications can be a lower-cost route, and the rules around them shifted as the recent shortages resolved [7]. Quality and physician oversight vary by source, so a compounded option should come from a licensed, supervised medical program using a reputable compounding pharmacy — not an anonymous online seller.

JumpstartMD prescribes and supervises these medications, including compounded options where appropriate.

Can you switch between them?

Yes — switching between Wegovy and Zepbound is common and is done under medical supervision. People often move from Wegovy to Zepbound for greater weight loss, or the other way for coverage or tolerability reasons.

Because they are different molecules and are not milligram-equivalent, a clinician restarts the dose ladder for the new drug rather than matching doses. You should not take both at once — combining two incretin drugs is not recommended [2].

Which is right for you?

• Your main goal is maximum weight loss → Zepbound has the strongest head-to-head evidence [3].
• You have heart disease with obesity → Wegovy has the proven cardiovascular benefit (SELECT) [6].
• You have obstructive sleep apnea with obesity → Zepbound is FDA-approved for that specific combination [2].
• Coverage is the obstacle → the answer often comes down to which one your plan will pay for.

The right answer depends on your goals, other conditions, insurance, and history — exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage both Wegovy and Zepbound, including dose titration and side-effect management.